DEC 13, 2017 2:35 PM PST

Study Finds Promise for Huntington's in a Cancer Drug

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

The most intricate man-made origami structure may pale in comparison to the body’s natural origamis: 3-dimenstional proteins. The folding of amino acids in specific arrangements create highly sophisticated proteins in composition, structure, and also function.

When this orchestrated process goes right, human biology is a well-oiled machine. However, when the folding is off even for just a little bit, the results can be devastating. In the case of Huntington’s disease, the huntingtin protein is misfolded causing the proteins to clump in the brain. These turn into toxic clusters that interfere with the function of neurons and leading to the mental and physical decline in patients.

Huntington’s disease is a neurodegenerative disorder that is progressive and fatal. In patients with the disease, the huntingtin protein is misfolded and these proteins form clumps in the brain. In turn, these proteinaceous clumps turn into toxic clusters that interfere with the function of neurons and leading to the mental and physical decline in patients. In addition to finding a cure for this tragic disease, researchers are also working to slow its progression.

Spurred by previous results involving repurposed drugs, researchers wanted to test whether a cancer drug can help patients with Huntington’s disease.

The research team involved top scientists from Duke University, the University of California, San Diego, the Salk Institute in La Jolla, CA, and the Johns Hopkins University in Maryland.

In this study, the repurposed drug is bexarotene (trade name: Targretin), an anti-cancer drug approved for the treatment of cutaneous T cell lymphoma. While this retinoid drug is FDA-approved for skin lymphoma, it has been prescribed off-label for other cancer types, including non-small cell lung cancer and breast cancer.

Using a mouse model of Huntington’s disease, the research team tested the effects of bexarotene on the marked degeneration typically associated with the disease.

Mice treated with bexarotene showed remarkable changes, including “improved motor function, reduced neurodegeneration, and increased survival.” These protective qualities appeared to stem from the drug’s ability to correct the oxidative metabolism in Huntinton’s disease neurons. Bexarotene also seemed to improve cell quality control. Overall, the drug seemed to correct activities that would otherwise be dysfunctional in Huntington’s disease.

"It's not just the response from the drugs, but the mechanistic pathways these drugs are targeting," said Dr. Albert La Spada at Duke University. "These pathways are relevant to other neurodegenerative disorders and potentially the aging process, itself in addition to Huntington's disease."

Although the results are promising, the team cautions that further studies are required before the rug can be confidently prescribed to help Huntington’s patients. Furthermore, the team thinks bexarotene may be more potent if combined with other therapies. In particular, preliminary tests in cells show that bexarotene taken with KD3010, a diabetes compound, yielded better results.

"With this approach, we could minimize side effects with lower doses of each compound, even when together the treatments provide a higher effect than either one alone,” said Dr. Audrey Dickey, the study’s lead author.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 06, 2020
Immunology
APR 06, 2020
Clearing the Path for Dendritic Cells to Eliminate Tumors
  Dendritic cells are the sentinels of the immune system and use their “tree-like” projections to prese ...
APR 09, 2020
Cancer
APR 09, 2020
The Unexpected Anti-Cancer Effects of the Human Telomerase
The research to find effective treatments and diagnosing tools in the fight against cancer has led to a thorough investi ...
APR 19, 2020
Drug Discovery & Development
APR 19, 2020
FDA Approves New Drug for Breast Cancer
The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced f ...
MAY 04, 2020
Cancer
MAY 04, 2020
A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy
Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These trea ...
MAY 05, 2020
Cancer
MAY 05, 2020
Can a face-aging app improve sun protection behavior?
Can a face-aging mobile app improve the skin cancer protection behavior of teenagers? A cluster-randomized clinical tria ...
MAY 29, 2020
Cancer
MAY 29, 2020
What can we do about drug-induced tetraploidy in cancer cells?
A paper published in the journal Trends in Cancer describes how cancer therapies sometimes fuel genetic changes in cells ...
Loading Comments...